Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Accurate diagnosis of dengue in the acute phase is crucial for proper patient management, reducing mortality rates, and enabling public health authorities to implement effective vector control measures. Our study, conducted during the 2024 dengue epidemic in Brazil, compared the results of a rapid dengue NS1 antigen detection assay with dengue RT-PCR using 300 serum specimens. Ninety-five percent of the patients reported symptoms consistent with dengue infection. We observed substantial agreement between the two tests (kappa = 0.8). The rapid NS1 test demonstrated 87 % sensitivity and 92.7 % specificity, using dengue RT-PCR as the gold standard. Our findings confirm that the rapid NS1 antigen detection test can be reliably used during the acute phase of dengue infection to provide an accurate diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jviromet.2025.115143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zika and dengue viruses differentially modulate host mRNA processing factors defining its virulence.
NAR Mol Med
April 2025
Tumor Vaccine and Biotechnology Branch, Division of Cellular Therapy 2, Office of Cellular Therapy and Human Tissue, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, United States.
Changes in global climate have contributed to increased tick and mosquito (vector) populations and subsequent vector-borne flavivirus infections in humans. This increase poses a threat to the safety of human-derived biologics such as cell and gene therapy. We conducted time-course transcriptomic and protein analyses to uncover host molecular factors driving the virulence of Zika virus (ZIKV) and Dengue virus (DENV) in relation to host defense mechanisms, as these viruses have caused recent flavivirus outbreaks.
View Article and Find Full Text PDFPlatelet dynamics and thrombocytopenia in dengue fever: A prospective cohort study from Shenzhen, China.
New Microbes New Infect
October 2025
Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Introduction: Dengue fever, the most prevalent arthropod-borne viral disease, causes ∼400 million infections annually. Although thrombocytopenia is commonly associated with dengue, how it evolves in relation to viral load and immune responses remains poorly understood. This study aimed to elucidate platelet-virus-immune interactions in acute dengue by systematically tracking of viral load, platelet parameters, and leukocyte dynamics.
View Article and Find Full Text PDFHealth literacy, attitudes and preventive practices concerning mosquitoes and mosquito-borne infections - A questionnaire survey in a German community.
One Health
December 2025
Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
Introduction: Climate variability and non-environmental factors such as travel and migration pose an increasing risk of vector-borne infectious diseases to extratropical regions. The European Centre for Disease Prevention and Control has reported autochthonous transmissions of dengue or West Nile virus in Italy, France, Spain, and Germany. Raising awareness and implementing protective measures against mosquitoes will therefore become increasingly relevant in Germany in the future.
View Article and Find Full Text PDFMultimodal Deep Learning for Generating Potential Anti-Dengue Peptides.
ACS Omega
September 2025
Division of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.
Dengue virus remains a significant global health threat, imposing a substantial disease burden on nearly half of the world's population. The urgent need for effective antiviral therapeutics, including therapeutic peptides targeting the Dengue virus, is critical in the current healthcare landscape. However, the availability of anti-Dengue peptides (ADPs) data remains limited in existing data sets, posing a challenge for computational modeling and discovery.
View Article and Find Full Text PDFNeutralizing monoclonal antibodies against dengue virus: a scoping review of preclinical and clinical development.
Virology
September 2025
Department of Medicine, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
Background: Dengue virus (DENV) is a major global health challenge, causing over 7.6 million reported cases in 2024. Neutralizing monoclonal antibodies (NmAbs) have emerged as promising therapeutics to address the limitations of vaccines and lack of antivirals, but their development is complicated by viral diversity, "breathing" dynamics, and antibody-dependent enhancement (ADE).
View Article and Find Full Text PDF